170 related articles for article (PubMed ID: 37681913)
1. Comparative Shotgun Proteomics Reveals the Characteristic Protein Signature of Osteosarcoma Subtypes.
Alaa M; Al-Shehaby N; Anwar AM; Farid N; Shawky MS; Zamzam M; Zaky I; Elghounimy A; El-Naggar S; Magdeldin S
Cells; 2023 Aug; 12(17):. PubMed ID: 37681913
[TBL] [Abstract][Full Text] [Related]
2. Potential Molecular Mechanisms of AURKB in the Oncogenesis and Progression of Osteosarcoma Cells: A Label-Free Quantitative Proteomics Analysis.
Pi WS; Cao ZY; Liu JM; Peng AF; Chen WZ; Chen JW; Huang SH; Liu ZL
Technol Cancer Res Treat; 2018; 18():1533033819853262. PubMed ID: 31122179
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma.
Liu Z; Liu B; Feng C; Li C; Wang H; Zhang H; Liu P; Li Z; He S; Tu C
Front Immunol; 2022; 13():1071636. PubMed ID: 36569869
[TBL] [Abstract][Full Text] [Related]
4. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
5. Distinct profiles of oxidative stress-related and matrix proteins in adult bone and soft tissue osteosarcoma and desmoid tumors: a proteomics study.
Rao UN; Hood BL; Jones-Laughner JM; Sun M; Conrads TP
Hum Pathol; 2013 May; 44(5):725-33. PubMed ID: 23063503
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach.
Scott MC; Sarver AL; Gavin KJ; Thayanithy V; Getzy DM; Newman RA; Cutter GR; Lindblad-Toh K; Kisseberth WC; Hunter LE; Subramanian S; Breen M; Modiano JF
Bone; 2011 Sep; 49(3):356-67. PubMed ID: 21621658
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Classifier Reveals Prognostic Osteosarcoma Microenvironment Molecular Subtypes.
Song YJ; Xu Y; Deng C; Zhu X; Fu J; Chen H; Lu J; Xu H; Song G; Tang Q; Wang J
Front Immunol; 2021; 12():623762. PubMed ID: 33959121
[TBL] [Abstract][Full Text] [Related]
8. Biological analysis of cancer specific microRNAs on function modeling in osteosarcoma.
Wang H; Tang M; Ou L; Hou M; Feng T; Huang YE; Jin Y; Zhang H; Zuo G
Sci Rep; 2017 Jul; 7(1):5382. PubMed ID: 28710380
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets.
Folio C; Mora MI; Zalacain M; Corrales FJ; Segura V; Sierrasesúmaga L; Toledo G; San-Julián M; Patiño-García A
J Proteome Res; 2009 Aug; 8(8):3882-8. PubMed ID: 19492781
[TBL] [Abstract][Full Text] [Related]
10. Expression of miR‑542‑3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways.
Li Z; Yao JN; Huang WT; He RQ; Ma J; Chen G; Wei QJ
Mol Med Rep; 2019 Feb; 19(2):974-983. PubMed ID: 30569116
[TBL] [Abstract][Full Text] [Related]
11. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling.
Zhang Y; Cheng H; Li W; Wu H; Yang Y
Int J Cancer; 2019 Aug; 145(4):1068-1082. PubMed ID: 30761524
[TBL] [Abstract][Full Text] [Related]
12. Plasma proteomic profiles of pain subtypes in adolescents and young adults with endometriosis.
Sasamoto N; Ngo L; Vitonis AF; Dillon ST; Sieberg CB; Missmer SA; Libermann TA; Terry KL
Hum Reprod; 2023 Aug; 38(8):1509-1519. PubMed ID: 37196326
[TBL] [Abstract][Full Text] [Related]
13. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
Zheng J; Liu C; Shi J; Wen K; Wang X
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
[TBL] [Abstract][Full Text] [Related]
14. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma.
Li Y; Dang TA; Shen J; Perlaky L; Hicks J; Murray J; Meyer W; Chintagumpala M; Lau CC; Man TK
Proteomics; 2006 Jun; 6(11):3426-35. PubMed ID: 16673437
[TBL] [Abstract][Full Text] [Related]
15. SIX1 reduces the expression of PTEN via activating PI3K/AKT signal to promote cell proliferation and tumorigenesis in osteosarcoma.
Yu C; Zhang B; Li YL; Yu XR
Biomed Pharmacother; 2018 Sep; 105():10-17. PubMed ID: 29807230
[TBL] [Abstract][Full Text] [Related]
16. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment.
Jiang Y; Wang J; Sun M; Zuo D; Wang H; Shen J; Jiang W; Mu H; Ma X; Yin F; Lin J; Wang C; Yu S; Jiang L; Lv G; Liu F; Xue L; Tian K; Wang G; Zhou Z; Lv Y; Wang Z; Zhang T; Xu J; Yang L; Zhao K; Sun W; Tang Y; Cai Z; Wang S; Hua Y
Nat Commun; 2022 Nov; 13(1):7207. PubMed ID: 36418292
[TBL] [Abstract][Full Text] [Related]
17. Characterizing the critical role of metabolism in osteosarcoma based on establishing novel molecular subtypes.
Zhang WB; Han FM; Liu LM; Jin HB; Yuan XY; Shang HS
Eur Rev Med Pharmacol Sci; 2022 Apr; 26(8):2926-2943. PubMed ID: 35503637
[TBL] [Abstract][Full Text] [Related]
18. Knocking down miR-384 promotes growth and metastasis of osteosarcoma MG63 cells by targeting SLBP.
Wang Y; Huang H; Li Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1458-1465. PubMed ID: 31007083
[TBL] [Abstract][Full Text] [Related]
19. Comparative proteomics analysis of human osteosarcomas and benign tumor of bone.
Li Y; Liang Q; Wen YQ; Chen LL; Wang LT; Liu YL; Luo CQ; Liang HZ; Li MT; Li Z
Cancer Genet Cytogenet; 2010 Apr; 198(2):97-106. PubMed ID: 20362224
[TBL] [Abstract][Full Text] [Related]
20. Upregulated LEPRE1 correlates with poor outcome and its knockdown attenuates cells proliferation, migration and invasion in osteosarcoma.
Huang Z; Wang Q; Wang Y; Zhao L; Cao Z; Cui C; Yu D; Liu B
Anticancer Drugs; 2020 Apr; 31(4):326-332. PubMed ID: 32197005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
